Literature DB >> 8383099

Relationship between the clinical course and HPV typing of recurrent laryngeal papillomatosis. The Red Cross War Memorial Children's Hospital experience 1982-1988.

A Padayachee1, C A Prescott.   

Abstract

During the period 1982-1988, 20 new cases of laryngeal papillomatosis in children were seen at The Red Cross War Memorial Children's Hospital. HPV typing of biopsy specimens was performed. Their clinical course was reviewed and age at presentation ranged from 1 to 10 years. There was no correlation between age and either aggression or a prolonged clinical course. HPV DNA was identified in all 20 cases (100%). Fifteen (75%) were HPV Type 11 and 5 (25%) were HPV Type 6. There were no mixed infections. HPV Type 6 infection was more clinically aggressive than HPV Type 11 infection. The intensity of the virus signal in the biopsy specimens was not in general indicative of the clinical behavior of the disease, although two children with particularly strong intensity exhibited aggressive disease. It is suggested that identification of HPV type 6 infection has prognostic significance.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383099     DOI: 10.1016/0165-5876(93)90019-y

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  8 in total

1.  Human papillomavirus and host variables as predictors of clinical course in patients with juvenile-onset recurrent respiratory papillomatosis.

Authors:  M Gabbott; Y E Cossart; A Kan; M Konopka; R Chan; B R Rose
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

2.  Laryngeal papillomatosis: morphological study by light and electron microscopy of the HPV-6.

Authors:  Regina Helena Garcia Martins; Norimar H Dias; Elisa Aparecida Gregório; Mariângela Alencar Marques; Márcia Guimarães da Silva; João Manuel Grisi Candeias
Journal:  Braz J Otorhinolaryngol       Date:  2008 Jul-Aug

3.  Risk factors for aggressive recurrent respiratory papillomatosis in adults and juveniles.

Authors:  Turid Omland; Harriet Akre; Kathrine A Lie; Peter Jebsen; Leiv Sandvik; Kjell Brøndbo
Journal:  PLoS One       Date:  2014-11-24       Impact factor: 3.240

4.  Clinical implications of alpha, beta, and gamma HPV infection in juvenile onset recurrent respiratory papillomatosis.

Authors:  Martina Bertinazzi; Tarik Gheit; Jerry Polesel; Sandrine McKay-Chopin; Cesare Cutrone; Marianna Sari; Marta Sbaraglia; Angelo Paolo Dei Tos; Piero Nicolai; Massimo Tommasino; Paolo Boscolo-Rizzo
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-08-28       Impact factor: 2.503

5.  HPV Strain Predicts Severity of Juvenile-Onset Recurrent Respiratory Papillomatosis with Implications for Disease Screening.

Authors:  Mary C Bedard; Alessandro de Alarcon; Yann-Fuu Kou; David Lee; Alexandra Sestito; Angela L Duggins; Marion Brusadelli; Adam Lane; Kathryn A Wikenheiser-Brokamp; Susanne I Wells; David F Smith
Journal:  Cancers (Basel)       Date:  2021-05-23       Impact factor: 6.639

6.  Juvenile-Onset Recurrent Respiratory Papillomatosis in the United States, Epidemiology and HPV Types-2015-2020.

Authors:  Raiza Amiling; Elissa Meites; Troy D Querec; Laura Stone; Vidisha Singh; Elizabeth R Unger; Craig S Derkay; Lauri E Markowitz
Journal:  J Pediatric Infect Dis Soc       Date:  2021-08-17       Impact factor: 5.235

7.  Age of child, more than HPV type, is associated with clinical course in recurrent respiratory papillomatosis.

Authors:  Farrel J Buchinsky; Joseph Donfack; Craig S Derkay; Sukgi S Choi; Stephen F Conley; Charles M Myer; John E McClay; Paolo Campisi; Brian J Wiatrak; Steven E Sobol; John M Schweinfurth; Domingos H Tsuji; Fen Z Hu; Howard E Rockette; Garth D Ehrlich; J Christopher Post
Journal:  PLoS One       Date:  2008-05-28       Impact factor: 3.240

Review 8.  Juvenile-Onset Recurrent Respiratory Papillomatosis Diagnosis and Management - A Developing Country Review.

Authors:  R Y Seedat
Journal:  Pediatric Health Med Ther       Date:  2020-02-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.